A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)
This article reports clinical trial results of a phase II trial assessing the efficacy of rucaparib in patients with high-risk biochemically recurrent nonmetast